Covered recipient · General Payments record
TICIANA A LEAL
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$77,172.49
74 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $52,898.50 | 16 |
| Honoraria | $17,605.00 | 7 |
| Travel and Lodging | $2,841.80 | 11 |
| Food and Beverage | $2,546.19 | 38 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,260.00 | 1 |
| Education | $21.00 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $18,774.00 | 1 |
| Regeneron Pharmaceuticals, Inc. | $9,777.85 | 18 |
| Catalyst Pharmaceuticals, Inc. | $8,802.92 | 7 |
| Novocure Inc. | $6,489.96 | 8 |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,950.00 | 1 |
| Amgen Inc. | $4,891.17 | 4 |
| G1 Therapeutics, Inc. | $3,696.95 | 3 |
| JAZZ PHARMACEUTICALS INC. | $3,392.00 | 1 |
| Gilead Sciences, Inc. | $3,228.92 | 2 |
| Janssen Biotech, Inc. | $2,800.00 | 2 |
| AstraZeneca UK Limited | $2,789.99 | 2 |
| E.R. Squibb & Sons, L.L.C. | $1,875.00 | 1 |
| PFIZER INC. | $1,504.06 | 3 |
| AstraZeneca Pharmaceuticals LP | $1,421.94 | 9 |
| Eisai Inc. | $1,360.00 | 1 |
| Genentech, Inc. | $760.00 | 1 |
| Daiichi Sankyo Inc. | $286.87 | 4 |
| Genentech USA, Inc. | $228.51 | 2 |
| Regeneron Healthcare Solutions, Inc. | $76.64 | 2 |
| Novartis Pharmaceuticals Corporation | $44.71 | 1 |
| Mirati Therapeutics, Inc. | $21.00 | 1 |
Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TICIANA A LEAL
NPI 1215129085 · CMS profile ID 369351
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ATLANTA, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215129085?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TICIANA A LEAL, NPI 1215129085, CMS profile ID 369351. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215129085?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). TICIANA A LEAL, NPI 1215129085, CMS profile ID 369351. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215129085?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- TICIANA A LEAL, NPI 1215129085, CMS profile ID 369351, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1215129085?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
74 matching records · $77,172.49 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–74 of 74.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca UK Limited | $49.99 | 06/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016997481 | CMS |
| Novocure Inc. | $90.30 | 05/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021073955 | CMS |
| Novocure Inc. | $3.00 | 05/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021073945 | CMS |
| Novocure Inc. | $504.80 | 05/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021073951 | CMS |
| AstraZeneca Pharmaceuticals LP | $101.41 | 05/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014991869 | CMS |
| AstraZeneca Pharmaceuticals LP | $40.63 | 04/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014338433 | CMS |
| G1 Therapeutics, Inc. | $80.00 | 04/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059918825 | CMS |
| Daiichi Sankyo Inc. | $10.32 | 03/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006501869 | CMS |
| Regeneron Healthcare Solutions, Inc. | $36.42 | 03/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999268563 | CMS |
| PFIZER INC. | $122.07 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049140149 | CMS |
| G1 Therapeutics, Inc. | $3,480.00 | 03/24/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059916671 | CMS |
| Mirati Therapeutics, Inc. | $21.00 | 03/20/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057996031 | CMS |
| Eisai Inc. | $1,360.00 | 03/08/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1023335291 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.98 | 03/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011570701 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.91 | 03/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015869251 | CMS |
| AstraZeneca Pharmaceuticals LP | $55.81 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011663985 | CMS |
| Daiichi Sankyo Inc. | $39.69 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006394763 | CMS |
| G1 Therapeutics, Inc. | $136.95 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059918671 | CMS |
| Catalyst Pharmaceuticals, Inc. | $750.00 | 02/20/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048227149 | CMS |
| Regeneron Pharmaceuticals, Inc. | $54.45 | 02/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000021611 | CMS |
| AstraZeneca Pharmaceuticals LP | $46.16 | 02/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014678639 | CMS |
| Catalyst Pharmaceuticals, Inc. | $33.02 | 02/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048225157 | CMS |
| Catalyst Pharmaceuticals, Inc. | $19.90 | 02/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048225159 | CMS |
| Daiichi Sankyo Inc. | $159.49 | 02/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006491117 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,936,932.39 | 97 |
| PY2024 | Principal investigator | $172,500.60 | 29 |
| PY2023 | Principal investigator | $45,041.00 | 3 |
| PY2022 | Principal investigator | $43,663.36 | 7 |
| PY2021 | Principal investigator | $581,537.74 | 22 |
| PY2020 | Recipient | $5,056.51 | 6 |
| PY2020 | Principal investigator | $828,750.03 | 33 |
| PY2019 | Principal investigator | $1,049,204.71 | 66 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
97 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $354,789.49 | 12/31/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow | No dispute reported | 06/30/2026 | 1232924216 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,644.00 | 12/22/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175389674 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $199.80 | 12/17/2025 | Non-covered Recipient Entity Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220996190 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $87,542.50 | 12/10/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797795 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $975.00 | 12/08/2025 | Non-covered Recipient Entity Lungprism LLC | DAREON-Lung-1: A Phase III multi-center, open-label, randomized trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs atezolizumab, carboplatin, and etoposide as first line treatment in patients with extensive-stage small cell lung cancer | No dispute reported | 06/30/2026 | 1220771511 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 12/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578016 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 12/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578018 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $35.92 | 12/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578020 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $35.92 | 12/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578022 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $20.98 | 12/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578024 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $19.98 | 12/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578026 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $378,606.44 | 11/30/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998183 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23,626.50 | 11/24/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797793 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $283,715.00 | 11/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220797835 |
| Principal investigator 1 | Amgen Inc. | $96,152.92 | 11/10/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | No dispute reported | 06/30/2026 | 1246637940 |
| Principal investigator 1 | Janssen Research & Development, LLC | $934.00 | 11/06/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175389601 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,035.00 | 11/03/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175389525 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 11/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578014 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,844.00 | 10/16/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220797833 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,608.40 | 10/14/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797791 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,168.00 | 10/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797783 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.00 | 10/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,056.00 | 10/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175389069 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,736.00 | 10/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175389373 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,112.00 | 10/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175389680 |
| Principal investigator 1 | Janssen Research & Development, LLC | $934.00 | 10/06/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175389529 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,536.00 | 10/03/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175389695 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 10/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578012 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $532,095.54 | 09/30/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998181 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,488.00 | 09/24/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220797831 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,738.00 | 09/15/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175389876 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,256.00 | 09/12/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797787 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.00 | 09/12/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797789 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $61,712.00 | 09/08/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797779 |
| Principal investigator 1 | Janssen Research & Development, LLC | $467.00 | 09/05/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175389831 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $111,030.00 | 09/03/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220797829 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 09/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578010 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119.88 | 08/26/2025 | Non-covered Recipient Entity Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220996188 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $263.70 | 08/26/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998171 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $139.92 | 08/26/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998173 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $179.82 | 08/26/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998175 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $15.96 | 08/26/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998177 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $7.20 | 08/26/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998179 |
| Principal investigator 1 | PFIZER INC. | $3,300.00 | 08/22/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228785382 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,884.00 | 08/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797775 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $88.00 | 08/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797777 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $72,423.25 | 08/04/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797781 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28,970.00 | 08/04/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220797827 |
| Principal investigator 1 | PFIZER INC. | $20,198.00 | 08/02/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228766428 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 08/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578008 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,978.00 | 07/22/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175389000 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $283.00 | 07/18/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797773 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $196,586.35 | 07/07/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797771 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 07/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578006 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,966.00 | 07/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175389335 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $23.32 | 06/24/2025 | Non-covered Recipient Entity Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220996184 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $399.60 | 06/24/2025 | Non-covered Recipient Entity Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220996186 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $146.50 | 06/24/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998163 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $233.20 | 06/24/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998165 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $99.90 | 06/24/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998167 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $26.60 | 06/24/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998169 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,660.00 | 06/20/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797769 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,958.00 | 06/02/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175389708 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 06/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578004 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119.88 | 05/27/2025 | Non-covered Recipient Entity Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220996182 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,373.36 | 05/08/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797767 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,092.00 | 05/08/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175389733 |
| Principal investigator 1 | Incyte Corporation | $264.00 | 05/07/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240473992 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 05/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578002 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,240.00 | 04/22/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175389153 |
| Principal investigator 1 | Eli Lilly and Company | $188,719.40 | 04/15/2025 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187877667 |
| Principal investigator 1 | Amgen Inc. | $103,469.98 | 04/14/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | No dispute reported | 06/30/2026 | 1246637954 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $62,372.25 | 04/10/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797765 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,178.76 | 04/09/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797763 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $107.76 | 04/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577996 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $41.95 | 04/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577998 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 04/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220578000 |
| Principal investigator 1 | Incyte Corporation | $334.00 | 03/28/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240473976 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $146.50 | 03/25/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998155 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $233.20 | 03/25/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998157 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $99.90 | 03/25/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998159 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $26.60 | 03/25/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998161 |
| Principal investigator 1 | Eli Lilly and Company | $5,465.92 | 03/25/2025 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187873717 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,028.84 | 03/12/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797761 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $223.08 | 03/11/2025 | Covered Recipient Teaching Hospital Emory University Hospital | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220797759 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 03/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577992 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $146.50 | 02/25/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998147 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $233.20 | 02/25/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998149 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $99.90 | 02/25/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998151 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $26.60 | 02/25/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220998153 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,521.40 | 02/19/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase III Double-blind Randomised Placebo-Controlled International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Non-small Cell Lung Cancer following Complete Tumour Resection | No dispute reported | 06/30/2026 | 1185542022 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 02/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577990 |
| Principal investigator 1 | Incyte Corporation | $440.88 | 01/17/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240473980 |
| Principal investigator 1 | Incyte Corporation | $160.00 | 01/17/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240473984 |
| Principal investigator 1 | Incyte Corporation | $132.00 | 01/17/2025 | Covered Recipient Teaching Hospital Emory University Hospital | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240473988 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $49,963.89 | 01/13/2025 | Covered Recipient Teaching Hospital Emory University Hospital | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185542024 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 01/01/2025 | Covered Recipient Teaching Hospital Emory University Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577994 |